-

Lazard Hires Geoffrey Porges to Healthcare Advisory Group

NEW YORK--(BUSINESS WIRE)--Lazard announced today that Dr. Geoffrey Porges has joined the firm as Managing Director in the Healthcare Advisory Group, advising on transactions across diversified biopharmaceuticals.

“Lazard’s deep expertise in healthcare and biopharma makes it an ideal platform to help clients tackle key strategic and financial challenges,” said Dr. Porges.

Share

“We are thrilled to welcome Geoffrey to Lazard,” said David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare. “His deep understanding of the biopharmaceutical industry's strategic and financial landscape, coupled with his ability to help companies translate scientific innovation into actionable business strategies, will empower our clients to strengthen their competitive positions, capitalize on growth opportunities, and build resilient companies in a challenging geopolitical and macroeconomic environment.”

Dr. Porges brings more than 30 years of experience in advisory, executive, and investment roles in the biopharmaceutical industry. Most recently, he served as EVP and Chief Financial Officer at Schrödinger, where he oversaw financial operations, investor relations, corporate communications, strategic planning and business development. Previously, he was the head of biopharma equity research at SVB Leerink and senior biotechnology equity research analyst Sanford C. Bernstein, consistently earning recognition as one of Wall Street’s top analysts. Earlier, Dr. Porges held senior roles at BTG PLC and Merck & Co.

“Lazard’s deep expertise in healthcare and biopharma makes it an ideal platform to help clients tackle key strategic and financial challenges,” said Dr. Porges. “I’m excited to join this world-class team and begin working with clients as they make critical decisions in a dynamic environment.”

Dr. Porges earned his medical degree from the University of Sydney and an MBA from Harvard Business School, where he was a Baker Scholar.

About Lazard

Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Lazard is listed on the New York Stock Exchange as Lazard, Inc. under the ticker LAZ. For more information, please visit Lazard.com and follow Lazard on LinkedIn.

LAZ-CPE

Contacts

Media Relations
Jessica Francisco, +1 212-632-6571
jessica.francisco@lazard.com
Shannon Houston, +1 212-632-6880
shannon.houston@lazard.com

Investor Relations
Alexandra Deignan, +1 212-632-6886
alexandra.deignan@lazard.com

Lazard, Inc.

NYSE:LAZ

Release Versions

Contacts

Media Relations
Jessica Francisco, +1 212-632-6571
jessica.francisco@lazard.com
Shannon Houston, +1 212-632-6880
shannon.houston@lazard.com

Investor Relations
Alexandra Deignan, +1 212-632-6886
alexandra.deignan@lazard.com

Social Media Profiles
More News From Lazard, Inc.

Lazard Reports October 2025 Assets Under Management

NEW YORK--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) reported today that its preliminary assets under management (“AUM”) as of October 31, 2025 totaled approximately $267.8 billion. The month’s AUM included market appreciation of $6.9 billion, net outflows of $1.4 billion and FX depreciation of $2.2 billion. LAZARD, INC. ASSETS UNDER MANAGEMENT (“AUM”) (unaudited) ($ in millions)     As of:   October 31, September 30,   20251 2025 Equity   $212,643 $208,510 Fixed Income   46,145 47,186 Other   8...

Lazard Brings Decades of Emerging Markets Leadership to the ETF Market With EMKT

NEW YORK--(BUSINESS WIRE)--Lazard Asset Management (“LAM”) today announced the successful conversion of the Lazard Emerging Markets Core Equity Portfolio into the Lazard Emerging Markets Opportunities Fund ETF (NYSE: EMKT). The actively managed ETF offers investors streamlined access to Lazard’s long-standing leadership in emerging markets investing through a high-conviction portfolio. For more than 30 years, Lazard has been at the forefront of identifying and investing in the companies, sector...

Lazard Reports Third Quarter and Nine Month 2025 Results

NEW YORK--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) today reported net revenue of $748 million and record adjusted net revenue1 of $725 million for the quarter ended September 30, 2025. For the first nine months of 2025, Lazard reported net revenue of $2,192 million and adjusted net revenue1 of $2,138 million. On a U.S. GAAP basis, Lazard reported third quarter 2025 net income of $71 million or $0.65 per share, diluted. For the first nine months of 2025, net income on a U.S. GAAP basis was $187...
Back to Newsroom